By Sherri Oslick --
About Court Report: Each week we will report briefly
on recently filed biotech and pharma patent cases. A few interesting cases will be selected for
periodic monitoring, providing our readers with an opportunity to follow the
progress of these cases.
Stratagene California v. Bio-Rad Laboratories Inc. et
al.
3:06-cv-02553; filed November 20, 2006 in the Southern
District of California
Infringement of U.S. Patent Nos. 6,054,263 ("Thermal
Cycler Including a Temperature Gradient Block," issued April 25, 2000) and
5,779,981 (same title, issued July 14, 1998) based on Bio-Rad's manufacture and
sale of various thermal cycler devices, and U.S. Patent Nos. 5,288,647
("Method of Irradiating Biological Specimens," issued February 22,
1994) and 5,395,591 ("Apparatus of Irradiating Biological Specimens,"
issued March 7, 1995) based on Bio-Rad's manufacture and sale of irradiating
devices, including Bio-Rad's GS Gene Linker UV® device. View the complaint here.
Barr Laboratories Inc. v. Aventis Pharmaceuticals, Inc.
2:06-cv-05605; filed November 21, 2006 in the District
Court of New Jersey
Declaratory judgment of invalidity, unenforceability, and noninfringement of U.S. Patent No. 7,138,524 ("Processes for Preparing Anhydrous and Hydrate Forms of Antihistaminic Piperidine Derivatives, Polymorphs and Pseudomorphs Thereof," issued November 21, 2006). The '524 patent covers a particular crystal form of fexofenadine hydrochloride (Aventis' Allegra®, used to treat allergies), as does U.S. Patent No. 7,135,571 (same title, issued November 14, 2006). Aventis asserted the '571 patent against Barr in a complaint filed on November 14, 2006 (2:06-cv-00469, ED Texas). View the complaint here.
Comments